Skip to content

Ponoi II Management, LLC

Follow

13F filer, CIK 1746488, San Francisco, CA

Ponoi II Management, LLC reported $123,394,000 across 5 holdings for the quarter ended 2021-06-30, in a 13F-HR filed 2021-08-16.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-21-011466

Period
2021-06-30
Reported value
$123M
Holdings
5
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q2 2021

Share positions as resolved from 13F-HR 0000950123-21-011466, largest first. % of portfolio is the value over $123,394,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q3: restricted; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 1,574,229 shares; 2021Q1: 1,574,229 shares; 2021Q2: 1,574,229 shares 1,574,229$53.2M43.12%0
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q3: restricted; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 1,298,908 shares; 2021Q1: 1,298,908 shares; 2021Q2: 1,298,908 shares 1,298,908$25.6M20.76%0
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q3: restricted; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 685,011 shares; 2021Q1: 685,011 shares; 2021Q2: 685,011 shares 685,011$21.7M17.62%0Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q3: restricted; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 686,274 shares; 2021Q1: 686,274 shares; 2021Q2: 686,274 shares 686,274$18.2M14.76%0Timeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q3: restricted; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 145,401 shares; 2021Q1: 145,401 shares; 2021Q2: 145,401 shares 145,401$4.62M3.75%0

How Q2 2021 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-21-011466 base2021-08-16acceptance time not in the bulk data set